Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label prophylaxis with Garadacimab (CSL312) in hereditary angioedema
2020-003918-12Phase 3Active
- Sponsor
- CSL Behring
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Behring. Primary endpoint: Number of subjects with treatment emergent adverse events (TEAEs). Started Nov 2020; status: active.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2020-003918-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003918-12.